Pomalidomide Rowex 3 mg hard capsules
Authorisation PA0711/338/003 · Rowex Limited,
- Licence holder
- Rowex Limited, (all products →)
- Active substance
- Pomalidomide
- Clinical trials
- 71 clinical trials →
- Dosage form
- Capsule, hard
- Route of administration
- Oral use
- ATC code
- L04AX06
- First authorised
- 06/09/2024
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Pomalidomide: supply and approvals
36 authorised products on the HPRA list contain Pomalidomide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 2 years (since 6 September 2024). The HPRA list marks it as marketed in Ireland.
Other medicines with Pomalidomide in Ireland
35 other products on the HPRA list contain Pomalidomide, from 9 licence holders; 6 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Pomalidomide Clonmel 1 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Pomalidomide Clonmel 2 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Pomalidomide Clonmel 3 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Pomalidomide Clonmel 4 mg hard capsules | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Pomalidomide Rowex 2 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Pomalidomide Rowex 4 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Imnovid 1 mg hard capsules | Bristol-Myers Squibb Pharma EEIG | Centralised EU authorisation | Not stated |
| Imnovid 2 mg hard capsules | Bristol-Myers Squibb Pharma EEIG | Centralised EU authorisation | Not stated |
| Imnovid 3 mg hard capsules | Bristol-Myers Squibb Pharma EEIG | Centralised EU authorisation | Not stated |
| Imnovid 4 mg hard capsules | Bristol-Myers Squibb Pharma EEIG | Centralised EU authorisation | Not stated |
| Pomalidomide Accord 1 mg hard capsules | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Pomalidomide Accord 2 mg hard capsules | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
The licence holder
Rowex Limited, holds 301 products on the HPRA list, with 139 different active substances; 213 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.